

## Lymphokines Enhance the Capacity of Human Monocytes to Secrete Reactive Oxygen Intermediates

Akira Nakagawara, ... , Nadia Nogueira, Carl F. Nathan

*J Clin Invest.* 1982;70(5):1042-1048. <https://doi.org/10.1172/JCI110691>.

### Research Article

Supernatants from mitogen- or antigen-stimulated human blood mononuclear cells enhanced the capacity of human monocytes or monocyte-derived macrophages (MDM) to release  $H_2O_2$  or  $O_2^-$  in response to phorbol myristate acetate or zymosan. The stimulatory effect of lymphokines (LK) lasted ~5 d, regardless of the time of their addition. However, the magnitude of stimulation depended on whether LK were added to freshly explanted monocytes or to MDM. When LK were added on day 0 of culture, they enhanced MDM  $H_2O_2$ -releasing capacity ~40% measured on day 3, when  $H_2O_2$ -releasing capacity in the controls was maximal. Addition of LK on day 2 retarded the decline in  $H_2O_2$ -releasing capacity normally seen by day 5, so that LK-treated cells released about twice as much  $H_2O_2$  as the controls. Addition of LK to MDM that had already lost most of their  $H_2O_2$ -releasing capacity (e.g., on day 4-6) restored it to an average of 60% of the values seen with freshly explanted monocytes. In this case, LK-treated cells were about 12 times more active than cells incubated in medium alone. The effects of LK were dose- and time-dependent, with maximal effects requiring 3 d of exposure. The specific activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, and myeloperoxidase, and the specific content of glutathione were not diminished in LK-treated MDM, suggesting that increased synthesis of  $H_2O_2$  [...]

Find the latest version:

<https://jci.me/110691/pdf>



# Lymphokines Enhance the Capacity of Human Monocytes to Secrete Reactive Oxygen Intermediates

AKIRA NAKAGAWARA, NANCY M. DESANTIS, NADIA NOGUEIRA, and CARL F. NATHAN,  
*The Rockefeller University, New York, New York 10021*

**ABSTRACT** Supernatants from mitogen- or antigen-stimulated human blood mononuclear cells enhanced the capacity of human monocytes or monocyte-derived macrophages (MDM) to release  $H_2O_2$  or  $O_2^-$  in response to phorbol myristate acetate or zymosan. The stimulatory effect of lymphokines (LK) lasted  $\sim 5$  d, regardless of the time of their addition. However, the magnitude of stimulation depended on whether LK were added to freshly explanted monocytes or to MDM. When LK were added on day 0 of culture, they enhanced MDM  $H_2O_2$ -releasing capacity  $\sim 40\%$  measured on day 3, when  $H_2O_2$ -releasing capacity in the controls was maximal. Addition of LK on day 2 retarded the decline in  $H_2O_2$ -releasing capacity normally seen by day 5, so that LK-treated cells released about twice as much  $H_2O_2$  as the controls. Addition of LK to MDM that had already lost most of their  $H_2O_2$ -releasing capacity (e.g., on day 4–6) restored it to an average of 60% of the values seen with freshly explanted monocytes. In this case, LK-treated cells were about 12 times more active than cells incubated in medium alone. The effects of LK were dose- and time-dependent, with maximal effects requiring 3 d of exposure. The specific activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, and myeloperoxidase, and the specific content of glutathione were not diminished in LK-treated MDM, suggesting that increased synthesis of  $H_2O_2$  rather than decreased catabolism probably explained the greater release of  $H_2O_2$  from LK-treated cells. In contrast, release of  $H_2O_2$  was suppressed  $93 \pm 4\%$  by exposing

monocytes for 4 d to hydrocortisone (50%-inhibitory concentration,  $1.9 \pm 0.3 \times 10^{-7}$  M). Thus, the oxidative metabolism of human mononuclear phagocytes can be markedly modulated in vitro: augmented by mediators released from lymphocytes during an immune response, and suppressed by antiinflammatory corticosteroids.

## INTRODUCTION

Studies with mouse peritoneal macrophages have revealed a close correlation between the capacity of the cells to release reactive oxygen intermediates (ROI)<sup>1</sup> such as hydrogen peroxide ( $H_2O_2$ ) and superoxide ( $O_2^-$ ), and their ability to inhibit the growth of certain intracellular pathogens (1–7). This has been demonstrated not only with macrophages activated in vivo by injection of microbial materials, but also with macrophages exposed in vitro to supernatants of antigen- or mitogen-stimulated lymphocytes (lymphokines [LK]) (1, 2, 5, 6). Incubation in LK enhanced the capacity of murine macrophages both to secrete  $H_2O_2$  and to kill *Trypanosoma cruzi* (1), *Toxoplasma gondii* (2), *Leishmania enriettii* (5), and *Mycobacterium microti* (6).

Human blood monocytes release large amounts of ROI when freshly explanted and challenged with suitable immunologic, pharmacologic, or particulate stimuli (8–12). However, as the cells mature into monocyte-derived macrophages (MDM) over  $\sim 5$  d in vitro, their capacity to secrete ROI declines sharply, until it comes to resemble that of the resident peritoneal macrophage of the mouse (12). Treatment of human

---

Address reprint requests to Dr. Nathan. Dr. Nathan is a Scholar of the Leukemia Society of America and a research career awardee of the Irma T. Hirsch Trust. Dr. Nogueira is a recipient of a research career development award in geographic medicine from the Rockefeller Foundation. Dr. Nakagawara's present address is Department of Pediatric Surgery, Kyushu University School of Medicine, Fukuoka 812, Japan.

Received for publication 20 April 1982 and in revised form 22 July 1982.

---

<sup>1</sup> Abbreviations used in this paper: Con A, concanavalin A; hk-BCG, heat-killed BCG;  $IC_{50}$ , 50%-inhibitory concentration; LK, lymphokines; LPS, bacterial lipopolysaccharide; MDM, monocyte-derived macrophages; MNL, mononuclear leukocytes; PMA, phorbol myristate acetate; PPD, purified protein derivative (tuberculin); ROI, reactive oxygen intermediates; SOD, superoxide dismutase.

mononuclear phagocytes with LK enhances their capacity to inhibit the intracellular replication of *T. gondii* (13, 14), *T. cruzi* (15), *Legionella pneumophila* (16), *Mycobacterium tuberculosis* (17), *Mycobacterium bovis* (17), and *Staphylococcus aureus* (18). We hypothesized, therefore, that treatment of human monocytes with LK would retard the normal decline in their capacity to secrete ROI, and that treatment of human MDM with LK would elevate their ROI-secreting capacity toward the high levels characteristic of activated rodent macrophages.

## METHODS

**Cultivation of human monocytes.** Blood monocytes were separated from buffy coat obtained from the Greater New York Blood Center, as reported previously (12). In brief, the cells were diluted twofold in 0.9% NaCl, layered on Ficoll-Hypaque ( $\rho = 1.077$ ) (Pharmacia Fine Chemicals, Piscataway, NJ), and centrifuged at 700 *g* for 20 min at 25°C. The mononuclear leukocytes (MNL) were collected, washed as described (12), and suspended in RPMI 1640 (Flow Laboratories, Inc., Rockville, MD) that contained 100  $\mu\text{g}/\text{ml}$  streptomycin, 100 U/ml penicillin, and 25% human serum prepared as reported (12). 0.1 ml of a suspension of  $1 \times 10^7$  MNL/ml was placed on a 13-mm-Diam glass cover slip (Clay-Adams, New York, NY) and incubated for 2 h at 37°C in 5%  $\text{CO}_2$ :95% humidified air. The nonadherent cells were removed by washing three times with Hanks' balanced salt solution (HBSS) or Eagle's minimum essential medium (Flow Laboratories) at 37°C. The cover slips were then placed in 0.3 ml of RPMI-25% human serum with antibiotics (12). The medium was replaced on days 1, 3, 5, and 7, unless indicated otherwise.

**Preparation of LK.** MNL were collected from purified protein derivative (tuberculin) (PPD)-positive donors as described above, except that the blood was anticoagulated with 40 U/ml heparin rather than citrate. 5 ml of cells ( $1 \times 10^7/\text{ml}$ ) in RPMI 1640 with 100  $\mu\text{g}/\text{ml}$  streptomycin, 100 U/ml penicillin,  $5 \times 10^{-7}$  M 2-mercaptoethanol, 2 mM glutamine, and 25% fresh autologous serum ("enriched RPMI") were incubated for 2 h in 5%  $\text{CO}_2$ :95% humidified air in an 84-mm-Diam plastic tissue culture dish. Nonadherent cells were collected by replacing the medium three times with warm HBSS while agitating the dish. The recovered cells were centrifuged and suspended in enriched RPMI at  $5 \times 10^6/\text{ml}$ . 4 ml of the cell suspension were incubated in 50-mm-Diam plastic tissue culture dishes with  $\sim 4 \times 10^4$  BCG (Pasteur type 1011; Trudeau Mycobacterial Collection, Trudeau Institute, Saranac Lake, NY), which had been heat-killed by autoclaving (heat-killed BCG [hk-BCG]). After 5 d at 37°C in 5%  $\text{CO}_2$ :95% humidified air, the medium was centrifuged to remove cells, dialyzed in Spectra/Por 6 tubing (cutoff, 1,000 daltons; Spectrum Medical Industries, Los Angeles, CA) for 24 h at 4°C against 100 volumes of RPMI 1640, sterilized by filtration (0.22  $\mu\text{m}$  pore size; Millex, Millipore Corporation, Bedford, MA), and stored at -20°C until use. This fluid was designated BCG-LK. Control LK was prepared in the same manner, except that hk-BCG were added at the end of the 5-d incubation. The "medium control" consisted of enriched RPMI that was incubated for 5 d without cells, given hk-BCG, centrifuged, dialyzed, filtered, and stored as above. Concanavalin A (Con A)-induced LK, control LK, and the Con A medium control were prepared as above, except that hk-BCG was replaced in each case by 20

$\mu\text{g}/\text{ml}$  Con A (Sigma Chemical Co., St. Louis, MO) and the supernate was collected at 2 d.

**Secretion of  $\text{H}_2\text{O}_2$  or  $\text{O}_2^-$ .** The assays were conducted as described (12), using the fluorometric detection of horseradish peroxidase-catalyzed oxidation of scopoletin to detect  $\text{H}_2\text{O}_2$ , and the spectrophotometric detection of superoxide dismutase (SOD)-inhibitable reduction of ferricytochrome *c* to detect superoxide anion. Phorbol myristate acetate (PMA) (100 ng/ml) (Consolidated Midland, Corp., Brewster, NY) or opsonized zymosan (50 particles per monocyte) were used to trigger secretion of ROI, as described (12). No secretion of ROI was detected in the absence of triggering agents. The data are usually expressed as the mean  $\pm$  SEM for triplicates, divided by the mean protein content of triplicate monolayers that were treated exactly like those used to measure secretion of ROI. Protein was measured by the method of Lowry et al. (19), using bovine serum albumin as a standard.

**Assays for  $\text{O}_2^-$  or  $\text{H}_2\text{O}_2$ -catabolizing factors.** SOD (20), catalase (21), glutathione (22), glutathione peroxidase (23), glutathione reductase (24), and myeloperoxidase (25) were measured by the cited methods, as described earlier (12), except that the concentration of Triton X-100 (Sigma Chemical Co.) in the cell lysate was 0.5%. This concentration of Triton X-100 did not affect the assays.

**Effects of hydrocortisone.** Where indicated, hydrocortisone phosphate (Sigma Chemical Co.) was added to the culture medium on day 0, and fresh medium containing the drug was replaced on day 2.

## RESULTS

**Dose-dependent effect of LK on  $\text{H}_2\text{O}_2$ -releasing capacity of human MDM.** Monocytes were incubated for 4 d in RPMI 1640 with 25% human serum. The MDM were then exposed for an additional 2 d to LK and control media. On day 6, the cells were washed and tested for their ability to release  $\text{H}_2\text{O}_2$  in response to PMA. As shown in Fig. 1, supernatant from lym-




FIGURE 1 Effect of concentration of BCG-LK on  $\text{H}_2\text{O}_2$  release from MDM. Monocytes were cultured for 4 d before LK and control media were added. Assays were performed 2 d later using PMA as a stimulus. Data are means  $\pm$  SEM for triplicates in a representative experiment. □, BCG-LK; ●, control medium; △, control LK.

phocytes of a PPD-positive donor cultured with hk-BCG (BCG-LK) doubled the  $H_2O_2$ -releasing capacity of the MDM, compared with MDM that had been cultured for the previous 2 d in RPMI 1640-human serum alone. This effect increased linearly with the concentration of BCG-LK over the range tested (2–30%). In contrast, no augmentation of  $H_2O_2$ -releasing capacity was seen after incubation in supernatant from the same lymphocytes to which hk-BCG was added just before removal of the lymphocytes (control LK). Likewise, RPMI 1640-human serum, which had been incubated for 5 d in parallel with the lymphocytes and exposed to BCG (medium control), did not increase the  $H_2O_2$ -releasing capacity of the MDM (Fig. 1).

The above LK were obtained from nonadherent MNL and were dialyzed against RPMI 1640 before use (14). When BCG-LK was prepared from unseparated MNL and used without dialysis, the dose-response curve usually peaked at lower concentrations than those shown in Fig. 1 (e.g., 2–5%), but showed suppressive effects at higher concentrations (e.g., 10–30%) (data not shown).

Dialyzed supernatants collected 2 d after stimulating nonadherent MNL with Con A (Con A-LK) gave results like those with BCG (Fig. 2). However, controls containing Con A also stimulated  $H_2O_2$ -releasing capacity (Fig. 2) (26).

$H_2O_2$ -releasing capacity was elevated by LK whether expressed per cover slip or per milligram cell protein on concurrently measured, identically treated cover slips. LK had no consistent effect on the amount of cell protein per cover slip (data not shown). However, LK-treated cells were usually more spread out than controls.




FIGURE 2 Effect of concentration of Con A-LK on  $H_2O_2$  release from MDM. Monocytes were cultured for 4 d before LK and control media were added. Assays were performed 2 d later, using PMA as a stimulus. Data are means  $\pm$  SEM for triplicates in a representative experiment.  $\square$ , Con A-LK;  $\bullet$ , control medium;  $\triangle$  control LK.




FIGURE 3 Kinetics of enhancement of  $H_2O_2$  release by 10% BCG-LK (open circles), control LK (open triangles), or control medium (open squares) added to MDM on day 4 of culture. Values for cells incubated in medium alone are indicated by crosses. On day 7, some of the MDM were removed from LK and control media, rinsed, and placed in medium alone for 1–3 additional days (closed symbols). Data are means  $\pm$  SEM for triplicates in a representative experiment, using PMA as a stimulus.

**Kinetics of LK effect.** Monocytes were tested for  $H_2O_2$  release on days 0, 1, 3, and 4 of culture (Fig. 3).  $H_2O_2$ -releasing capacity declined to 21% of the initial level by 4 d. At that point, the remaining MDM were incubated in 10% BCG-LK, control LK, or medium alone, for intervals ranging up to an additional 6 d. As shown in Fig. 3, 1 d of exposure to BCG-LK maintained  $H_2O_2$  release at the same level as on day 4. In contrast,  $H_2O_2$  release from MDM incubated from day 4 to 5 in control LK, control medium, or fresh medium alone continued to decline, reaching  $\sim$ 4% of the day 0 value. After 2–3 d incubation in BCG-LK,  $H_2O_2$ -releasing capacity rose to 70% of the level seen on day 0. Thus, by the 7th d of culture, LK-treated MDM released from 9 to 30 times more  $H_2O_2$  per milligram cell protein than the controls. Thereafter,  $H_2O_2$ -releasing capacity of LK-treated MDM fell sharply, although it remained higher than concurrent controls at all times tested. This decline was hastened when LK was replaced with fresh medium (Fig. 3).

Next, we examined the effect of adding BCG-LK for 3-d periods beginning on each of the first 7 d of culture. As shown in Table I, the rise in  $H_2O_2$ -releasing capacity usually seen on days 2–4 was higher when BCG-LK was present. The decline in  $H_2O_2$ -releasing capacity usually seen on days 5–6 was delayed by BCG-LK. Thus, monocytes treated with LK from days 2–5 released 96% as much  $H_2O_2$  as those tested on day 0, whereas the controls released only 42% as much. After day 5,  $H_2O_2$ -releasing capacity declined in all

TABLE I  
Effect of the Time of Addition of BCG-LK on H<sub>2</sub>O<sub>2</sub> Release from Cultured Human Monocytes\*

Incubation period	H <sub>2</sub> O <sub>2</sub>		
	12% BCG-LK	12% Control LK	12% Control medium
	nmol/60 min per mg protein		
Day 0	—	—	425±6†
Day 0-3	827±107	455±114	609±46
Day 1-4	984±52	603±16	602±20
Day 2-5	410±22	198±24	180±24
Day 3-6	342±89	237±47	73±13
Day 4-7	122±9	51±15	73±11
Day 5-8	64±6	25±4	17±4
Day 6-9	38±3	0±0	0±0

\* After the indicated periods of incubation, cover slips with adherent cells were rinsed and exposed to PMA to trigger the release of H<sub>2</sub>O<sub>2</sub>.

† Means±SEM from triplicate or quadruplicate cultures, except duplicate values for the controls assayed on day 3.

cultures, remaining relatively higher in those exposed to LK.

There was considerable experiment-to-experiment variation in the effect of LK added on different days of culture (compare Table I and Fig. 3); however, the observations emphasized above were repeatedly observed. Thus, in three experiments in which LK was added from day 0 to day 3, LK-treated cells released 1.4±0.3 (mean±SEM) times as much H<sub>2</sub>O<sub>2</sub> per milligram cell protein on day 3 as did untreated cells on day 0, and 1.9±0.1 times as much as cells incubated in control media from day 0 to day 3. In five experiments in which H<sub>2</sub>O<sub>2</sub> release on days 6-8 was compared to that of the same cell preparations on day 0, exposure to LK for 2-3 d resulted in 0.6±0.2 times as much H<sub>2</sub>O<sub>2</sub> per milligram cell protein as for the freshly explanted cells, whereas samples of the same cells incubated 6-8 d in medium alone released only 0.06±0.03 times as much as on day 0. When MDM were exposed to LK for 2-3 d beginning on days 3-8 of culture, they released 4.0±0.9 times as much H<sub>2</sub>O<sub>2</sub> per milligram cell protein as cells incubated concurrently in control LK (17 experiments), 6.3±2.0 times as much as cells in control medium (14 experiments), and 11.8±5.5 times as much as in medium alone (11 experiments).

*Effects of LK assayed with another stimulus for H<sub>2</sub>O<sub>2</sub> release and another assay for ROI.* Either BCG-LK or Con A-LK augmented the release of ROI from MDM, whether PMA or opsonized zymosan was used as a stimulus, and whether H<sub>2</sub>O<sub>2</sub> or O<sub>2</sub><sup>-</sup> was measured (Table II). However, the amounts of O<sub>2</sub><sup>-</sup> detected were much lower than the amounts of H<sub>2</sub>O<sub>2</sub> measured si-

multaneously in matched cultures. The reason for the differential detection of H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub><sup>-</sup> is not known. It was unaffected by including 1,000-2,000 Sigma units of catalase per milliliter in the assay for O<sub>2</sub><sup>-</sup> to prevent possible reoxidation of ferrocytochrome *c* by H<sub>2</sub>O<sub>2</sub> (27) (ratio of ferrocytochrome *c* detected with catalase:without catalase = 0.9±0.1 in four experiments).

*Effects of LK on the activity of intracellular scavengers of ROI.* LK might increase ROI-secreting capacity either by augmenting synthesis of ROI, or by decreasing intracellular catabolism of ROI. To investigate the latter possibility, we cultured MDM in BCG-LK, Con A-LK, or control media, and measured the specific activity of SOD, myeloperoxidase, catalase, glutathione peroxidase, and glutathione reductase, and the specific content of glutathione. As shown in Table III, all media containing Con A tended to increase the specific activity of SOD. None of the experimental media affected any of the other intracellular scavengers of ROI.

*Effect of hydrocortisone on H<sub>2</sub>O<sub>2</sub>-releasing capacity.* The experiments described above suggested that H<sub>2</sub>O<sub>2</sub>-releasing capacity of monocytes and MDM could be augmented by exposure to LK. We were interested to learn whether H<sub>2</sub>O<sub>2</sub>-releasing capacity could also be modulated downward. To test this, we exposed monocytes to hydrocortisone, which in pharmacologic doses can decrease the ability of the host to handle infections by intracellular pathogens (28). As shown in Fig. 4, H<sub>2</sub>O<sub>2</sub> release from monocytes was nearly abolished by 4 d of exposure to 3 × 10<sup>-7</sup> M hydrocortisone. 2 d of exposure to concentrations as much as 33-fold higher were without effect (Fig. 4), and 3 d of exposure gave an intermediate effect (data not shown). In three separate experiments like that shown in Fig. 4, 4 d of exposure to hydrocortisone inhibited

TABLE II  
Effect of LK on H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub><sup>-</sup> Release Triggered by PMA or Opsonized Zymosan\*

Treatment	PMA		Opsonized zymosan	
	H <sub>2</sub> O <sub>2</sub>	O <sub>2</sub> <sup>-</sup>	H <sub>2</sub> O <sub>2</sub>	O <sub>2</sub> <sup>-</sup>
	nmol/60 min per mg protein			
12% Control LK	74±6	54±2	98±13	43±0.3
12% BCG-LK	303±19	71±3	216±28	65±0.6
10% Control LK	104±17	24±9	54±29	43±1.8
10% Con A-LK	267±25	64±13	164±17	90±21

Data are means±SEM from three experiments.

\* LK was added on day 4 and replaced on day 6. The assays were conducted on day 8.

TABLE III  
Effect of LK on Scavengers of  $O_2^-$  and  $H_2O_2$  within MDM\*

Treatment†	Superoxide dismutase	Myeloperoxidase	Catalase	Glutathione peroxidase	Glutathione reductase	Glutathione (GSH + GSSG)
	U/mg protein	$\times 10^{-3}$ U/mg protein	$\times 10^{-3}$ U/mg protein	nmol/min/mg protein	nmol/min/mg protein	nmol/mg protein
Con A system						
Medium alone	38±5 (4)	0.38±0.07 (2)	11.4±2.5 (3)	154±48 (3)	70±15 (3)	35.0±3.3 (4)
Medium control	57±9 (4)	0.44±0.0 (2)	13.4±0.7 (3)	156±22 (3)	74±8 (3)	41.9±2.1 (4)
Control LK	62±7 (4)	0.45±0.07 (2)	12.1±1.1 (3)	141±20 (3)	70±10 (3)	39.5±3.5 (4)
Con A-LK	69±10 (4)	0.49±0.04 (2)	12.1±1.2 (3)	145±7 (3)	68±4 (3)	40.6±2.5 (4)
BCG system						
Medium alone	35	0.45	8.8	203	49	34.3
Medium control	36	0.51	8.1	177	38	38.6
Control LK	32	0.49	10.1	247	55	43.7
BCG-LK	38	0.47	10.4	249	49	45.2

\* Mean±SEM for the number of experiments indicated in parentheses. Data for BCG system are from one experiment. LK were added on day 4 and assays conducted on days 7, 8, or 9.

† LK and medium control added at 10% (vol/vol).

$H_2O_2$  release from MDM by 93±4% (mean±SEM), with a 50%-inhibitory concentration ( $IC_{50}$ ) of  $1.9\pm 0.3 \times 10^{-7}$  M. Concentrations of hydrocortisone that suppressed  $H_2O_2$  release were not toxic to MDM, as judged by both the morphology and the amounts of adherent cell protein of treated monolayers as compared with untreated controls.

## DISCUSSION

Over the last 10 years, many changes in human monocytes or MDM have been observed after incu-




FIGURE 4 Effect of hydrocortisone on  $H_2O_2$  release in response to PMA. Hydrocortisone phosphate was added at the indicated concentrations on day 0 and assays conducted on day 2 or on day 4. In the latter case, fresh medium containing hydrocortisone was added on day 2. Data are mean±SEM of triplicates in a representative experiment.

bation in LK. These include enhanced adherence (29), oxidation of the first carbon of glucose (29), synthesis of nuclear RNA (30), phagocytosis of latex particles (30), activity of plasminogen activator (31), expression of Fc receptors (32), and cytotoxicity toward tumor cells (33, 34). Except for the last two features, most of these changes have been small. Moreover, none of them is likely to be directly related to the enhanced antimicrobial activity of LK-treated human mononuclear phagocytes observed with certain protozoal (13-15) and bacterial (16-18) pathogens. In contrast, the LK-induced enhancement of ROI-secreting capacity described in the present study may represent a close biochemical correlate of macrophage activation in man, as it does in the mouse (1-6). To establish such a correlation firmly, further studies will be needed in which oxidative metabolism and antimicrobial activity are measured in the same cell populations (18) and altered in parallel by a variety of interventions.

Antigen- or mitogen-induced lymphocyte products had different effects on the  $H_2O_2$ -secreting capacity of human blood-derived mononuclear phagocytes, depending on the time of addition of LK to the cultures. These differences appeared to reflect the time-dependent changes in ROI-secreting capacity that occurred spontaneously in untreated cultures. Thus, if LK were added to early cultures that could still secrete copious  $H_2O_2$ , LK elevated this capacity slightly during the first few days of incubation, and then delayed the decline usually observed by the fifth day. On the other hand, if LK were added to MDM that had already lost most of their capacity to secrete ROI, then  $H_2O_2$  release was restored much of the way toward the high levels characteristic of freshly explanted monocytes.

These levels came within the range of values seen with mouse peritoneal macrophages activated in vivo or in vitro (1-6).

With time, ROI-secreting capacity of human MDM always declined to levels characteristic of mature macrophages from the uninflamed peritoneal cavity of the mouse. That is, the enhancement by LK of H<sub>2</sub>O<sub>2</sub>-releasing capacity was limited to a total period of ~5 d, regardless of the concentration of LK or the time or frequency of its addition. It is not known if the transient nature of the action of LK reflects a physiologic response to the initial stimulus; a sequence of responses to a mixture of mediators, some of which may have a suppressive effect; an eventual response of the macrophage to some of its own secretory products, perhaps those induced by LK, such as prostaglandins (35); or a deficiency in some aspect of the in vitro environment.

The factors in the lymphoid supernatants responsible for augmenting ROI-secreting capacity have not been characterized. Thus, we do not know their relation to previously described LK that affect macrophages, such as migration inhibitory factor (36) or macrophage-activating factor (37, 38). Pabst et al. recently demonstrated an effect of bacterial lipopolysaccharide (LPS) on the O<sub>2</sub><sup>-</sup>-secreting capacity of human monocytes (39). Traces of LPS may have been present in our media. However, all components added to LK-rich media were also added to control media. The control media differed only in the time of addition of antigen or mitogen. Thus, any effects of LPS should have been present also in the controls. However, this leaves open the possibility of a synergistic interaction between LPS and LK (40).

LK did not alter the activity in human MDM of a wide variety of intracellular scavengers of ROI. Con A led to an increase in SOD activity, but this was not attributable to LK. Thus, it is most likely that increased detection of H<sub>2</sub>O<sub>2</sub>, released by MDM after exposure to LK, reflected increased synthesis of H<sub>2</sub>O<sub>2</sub>. As yet we have no information as to whether this results from induction of an oxidase or one of its cofactors or activators, or decreased activity of a regulator.

The H<sub>2</sub>O<sub>2</sub>-releasing capacity of human monocytes could be modulated downward as well as upward. This was shown with hydrocortisone, which nearly ablated detectable H<sub>2</sub>O<sub>2</sub>-releasing capacity in a dose- and time-dependent manner. The effective concentrations of hydrocortisone (IC<sub>50</sub>, 2 × 10<sup>-7</sup> M) are within the physiologic range. However, in the normal host, diurnal declines in cortisol levels may forestall the suppression of H<sub>2</sub>O<sub>2</sub> release seen here with sustained exposures lasting 3-4 d. The need for such prolonged exposure may explain why much smaller suppressive effects were noted by Lehmeier and Johnston, who added 10<sup>-3</sup> M prednisolone to human monocytes only at the

time of assay for ROI (41). Likewise, Masur et al. did not observe decreased release of ROI from activated mouse peritoneal macrophages exposed to 2 × 10<sup>-4</sup> M hydrocortisone for 24 h (42). The suppression of H<sub>2</sub>O<sub>2</sub>-releasing capacity of mononuclear phagocytes by prolonged exposure to hydrocortisone might be one factor in the tendency of pharmacologic doses of corticosteroids to reduce host resistance to a number of microbial pathogens (28).

It seems likely that there is a stage in the development of mononuclear phagocytes when the marrow precursor cannot mount a respiratory burst. By the time the monocyte circulates, it is endowed with the remarkable ability to respond to membrane stimulation by rapidly metabolizing large amounts of molecular oxygen to incompletely reduced and potentially toxic intermediates. However, the monocyte appears destined to lose much of this capacity as it matures into a macrophage, at least in vitro. At this point, its oxidative metabolism closely resembles that of the resident macrophage in the uninflamed mouse peritoneal cavity. The present findings suggest that during an immune response, lymphocytes release products, under the influence of which the oxidative metabolism of human mononuclear phagocytes can be markedly and reversibly enhanced.

#### ACKNOWLEDGMENTS

We thank Dr. Z. A. Cohn for his advice and support.

This research was supported by grant CA-22090 from the National Cancer Institute.

#### REFERENCES

1. Nathan, C., N. Nogueira, C. Juangbhanich, J. Ellis, and Z. A. Cohn. 1979. Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of *Trypanosoma cruzi*. *J. Exp. Med.* **149**: 1056-1068.
2. Murray, H. W., and Z. A. Cohn. 1980. Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. *J. Exp. Med.* **152**: 1596-1609.
3. Sasada, M., and R. B. Johnston, Jr. 1980. Macrophage microbicidal activity. Correlation between phagocytosis-associated oxidative metabolism and the killing of candida by macrophages. *J. Exp. Med.* **152**: 85-98.
4. Wilson, C. B., V. Tsai, and J. S. Remington. 1980. Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. *J. Exp. Med.* **151**: 328-346.
5. Buchmüller, Y., and J. Mauel. 1981. Studies on the mechanisms of macrophage activation: possible involvement of oxygen metabolites in killing of *Leishmania enrietti* by activated mouse macrophages. *J. Reticuloendothel. Soc.* **29**: 181-192.
6. Walker, L., and D. B. Lowrie. 1981. Killing of *Mycobacterium microti* by immunologically activated macrophages. *Nature (Lond.)* **293**: 69-70.
7. Nathan, C. F., and A. Nakagawara. 1982. Role of reactive oxygen intermediates in macrophage killing of intracellular pathogens: a review. *In Self-Defense Mech-*

- anisms: Role of Macrophages. A Naito Foundation Symposium. D. Mizuno, Z. A. Cohn, K. Takeya, and N. Ishida, editors. University of Tokyo Press, Tokyo, and Elsevier Biomedical Press, New York. 279-294.
8. Johnston, R. B., Jr., J. E. Lehmeyer, and L. A. Guthrie. 1976. Generation of superoxide anion and chemiluminescence by human monocytes during phagocytosis and on contact with surface bound immunoglobulin G. *J. Exp. Med.* **143**: 1551-1556.
  9. Reiss, M., and D. Roos. 1978. Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. *J. Clin. Invest.* **61**: 480-488.
  10. Weiss, S. J., G. W. King, and A. F. LoBuglio. 1978. Superoxide generation by human monocytes and macrophages. *Am. J. Hematol.* **4**: 1-8.
  11. Kitagawa, S., F. Takaku, and S. Sakamoto. 1980. A comparison of the superoxide-releasing response in human polymorphonuclear leukocytes and monocytes. *J. Immunol.* **125**: 359-364.
  12. Nakagawara, A., C. F. Nathan, and Z. A. Cohn. 1981. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. *J. Clin. Invest.* **68**: 1243-1252.
  13. Borges, J. S., and W. D. Johnson, Jr. 1975. Inhibition of multiplication of *Toxoplasma gondii* by human monocytes exposed to T-lymphocyte products. *J. Exp. Med.* **141**: 483-496.
  14. Anderson, S. E., S. Bautista, and J. S. Remington. 1976. Induction of resistance to *Toxoplasma gondii* in human macrophages by soluble lymphocyte products. *J. Immunol.* **117**: 381-387.
  15. Nogueira, N., S. Chaplan, M. Reesink, J. Tydings, and Z. A. Cohn. 1982. *Trypanosoma cruzi*: induction of microbicidal activity in human mononuclear phagocytes. *J. Immunol.* **128**: 2142-2146.
  16. Horwitz, M. A., and S. C. Silverstein. 1981. Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria. *J. Exp. Med.* **154**: 1618-1635.
  17. Crowle, A., and M. May. 1981. Preliminary demonstration of human tuberculoimmunity *in vitro*. *Infect. Immun.* **31**: 453-464.
  18. Greening, A. P., A. D. M. Rees, and D. B. Lowrie. 1981. Enhancement of human alveolar macrophage function by lymphokines. *Thorax*. **36**: 717-718 (Abstr.).
  19. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265-275.
  20. McCord, J. M., and I. Fridovich. 1969. Superoxide dismutase. An enzymic function for erythrocyte. *J. Biol. Chem.* **244**: 6049-6055.
  21. Baudhuin, P., H. Beaufay, Y. Rahman-Li, O. Z. Sellinger, R. Wattiaux, P. Jacques, and C. de Duve. 1964. Tissue fractionation studies. 17. Intracellular distribution of monoamine oxidase, aspartate aminotransferase, D-amino acid oxidase, and catalase in rat liver tissue. *Biochem. J.* **92**: 179-184.
  22. Tietze, F. 1969. Enzymic method for quantitative determination of nanogram amounts, of total and oxidized glutathione: applications to mammalian blood and other tissues. *Anal. Biochem.* **27**: 502-522.
  23. Paglia, D. E., and W. N. Valentine. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J. Lab. Clin. Med.* **70**: 158-169.
  24. Roos, D., R. S. Weening, A. A. Voetman, M. L. J. van Schaik, A. A. M. Bot, L. J. Meerhof, and J. A. Loos. 1979. Protection of phagocytic leukocytes by endogenous glutathione: studies in a family with glutathione reductase deficiency. *Blood*. **53**: 851-866.
  25. Steinman, R. M., and Z. A. Cohn. 1972. The interaction of soluble horseradish peroxidase with mouse peritoneal macrophages in vitro. *J. Cell Biol.* **55**: 186-204.
  26. Romeo, D., G. Zabucchi, and F. Rossi. 1973. Reversible metabolic stimulation of polymorphonuclear leukocytes and macrophages by concanavalin A. *Nat. New Biol.* **243**: 111-112.
  27. Klebanoff, S. J. 1974. Role of the superoxide anion in the myeloperoxidase-mediated antimicrobial system. *J. Biol. Chem.* **249**: 3724-3728.
  28. Dale, D. C., and R. G. Petersdorf. 1973. Corticosteroids and infectious diseases. *Med. Clin. N. Amer.* **57**: 1277-1287.
  29. Rocklin, R. E., C. T. Winston, and J. R. David. 1974. Activation of human blood monocytes by products of sensitized lymphocytes. *J. Clin. Invest.* **53**: 559-564.
  30. Schmidt, M. E., S. D. Douglas, and A. D. Rubin. 1973. Human monocyte activation by supernatants from concanavalin A (Con A) stimulated lymphocytes. *Cell. Immunol.* **9**: 45-59.
  31. Greineder, D. K., K. J. Connorton, and J. R. David. 1979. Plasminogen activator production by human monocytes. I. Enhancement by activated lymphocytes and lymphocyte products. *J. Immunol.* **123**: 2808-2813.
  32. Guyre, P. M., G. R. Crabtree, J. E. Bodwell, and A. Munck. 1981. MLC-conditioned media stimulate an increase in Fc receptors on human macrophages. *J. Immunol.* **126**: 666-668.
  33. Hammerstrom, J., G. Unsgaard, and J. Lamvik. 1979. Activation of human monocytes by mediators from lymphocytes stimulated with *Corynebacterium parvum*. *Acta Path. Microbiol. Scand. Sect. C. Immunol.* **87**: 167-175.
  34. Cameron, D. J., and W. H. Churchill. 1979. Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators. *J. Clin. Invest.* **63**: 977-984.
  35. Taffet, S. M., and S. W. Russell. 1981. Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. *J. Immunol.* **126**: 424-427.
  36. Remold, H. G., P. L. McCarthy, Jr., and A. D. Mednis. 1981. Purification of guinea pig pH 3 migration inhibitory factor. *Proc. Natl. Acad. Sci. USA*. **78**: 4088-4091.
  37. Nathan, C. F., M. L. Karnovsky, and J. R. David. 1971. Alterations of macrophage functions by mediators from lymphocytes. *J. Exp. Med.* **133**: 1356-1376.
  38. Nathan, C. F., H. G. Remold, and J. R. David. 1973. Characterization of a lymphocyte factor which alters macrophage functions. *J. Exp. Med.* **137**: 275-290.
  39. Pabst, M. J., H. B. Hedegaard, and R. B. Johnston, Jr. 1982. Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response. *J. Immunol.* **128**: 123-128.
  40. Pace, J. L., and S. W. Russell. 1981. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. *J. Immunol.* **126**: 1863-1868.
  41. Lehmeyer, J. E., and R. B. Johnston, Jr. 1978. Effect of antiinflammatory drugs and agents that elevate intracellular cyclic AMP on the release of toxic oxygen metabolites by phagocytes: studies in a model of tissue-bound IgG. *Clin. Immunol. Immunopathol.* **9**: 482-490.
  42. Masur, H., H. W. Murray, and T. C. Jones. 1982. Effect of hydrocortisone on macrophage response to lymphokine. *Infect. Immun.* **35**: 709-714.